Advanced NanoTherapies

Pre-clinical

San Diego, United StatesFounded 2018advancednanotherapies.com

Advanced NanoTherapies is pioneering a nanotechnology-based drug delivery platform to revolutionize the treatment of vascular diseases. The company's core innovation is a drug-agnostic, biodegradable nanoparticle system that enables sustained, in-tissue release of synergistic drug combinations, starting with its SirPlux Duo DCB for CAD and PAD. Key achievements include an exclusive license from Cleveland Clinic, FDA Breakthrough Device Designation for below-the-knee (BTK) applications, and established strategic partnerships. A.N.T. aims to expand its platform beyond cardiovascular applications into neurology, ENT, and orthopedics.

Founded

2018

Focus

Nanotechnology

AI Company Overview

Technology Platform

A proprietary, drug-agnostic nanoparticle delivery platform that enables sustained, in-tissue release of single or multiple drug combinations from medical devices like drug-coated balloons. The platform uses 100% biodegradable, functionalized nanoparticles for enhanced drug retention and lower required doses.

Funding History

Total raised: $2.5M

Seed$2.5MUndisclosedMay 15, 2021

Opportunities

The primary opportunity is to disrupt the large and growing market for coronary and peripheral vascular interventions with a superior, stent-like DCB.

Long-term, the drug-agnostic nanoparticle platform offers a pipeline-in-a-product opportunity, enabling expansion into neurology, ENT, orthopedics, and other therapeutic areas requiring localized, sustained drug delivery.

Risk Factors

Key risks include the failure of lead candidate SirPlux Duo in upcoming clinical trials, challenges in scaling manufacturing, the ability to secure sufficient funding to reach commercialization, and intense competition from established medical device giants with entrenched market positions.

Competitive Landscape

A.N.T. competes against major players like Philips (Stellarex), BD (Lutonix), and Medtronic (IN.PACT) in the DCB market. Its differentiation is based on a dual-drug (Sirolimus+Paclitaxel) nanoparticle platform that claims superior drug retention, lower dosing, no flaking, and better pre-clinical outcomes compared to existing single-drug, non-nanoparticle DCBs and drug-eluting stents.